Skip to main content
padlock icon - secure page this page is secure

Free Content Linezolid for the treatment of patients with atypical mycobacterial infection: a systematic review [Review Article]

Download Article:
(PDF 63.6 kb)
We searched PubMed and Cochrane databases to review the available evidence regarding the use of linezolid in combination with other drugs for the treatment of patients with mycobacterial infection. Case reports, case series, prospective and retrospective studies, and randomized controlled trials were eligible for inclusion in our systematic review if they evaluated the effectiveness and safety of linezolid for the treatment of patients with mycobacterial infection. Four studies were available, including 24 cases of patients with atypical mycobacterial infection. Cure of the infection, defined as sterilization of mycobacterial cultures or resolution of symptoms, was achieved in 15 of the 24 cases (62.5%) with mycobacterial infection (mainly tuberculosis). Sterile cultures were also achieved in three other cases, although the patients had stopped linezolid (two because of optic neuropathy and one due to economic reasons; all three continued on second-line therapy). On the other hand, serious adverse events were observed in the majority of patients with mycobacterial infection treated with combinations that included linezolid (18/24, 75%). Neuropathy (peripheral and/or optic) and anemia were reported in 11/24 (45.8%) and 10/24 (41.7%) cases, respectively. Although the limited evidence suggests that linezolid may be considered as a second-line agent for mycobacterial infections, any treatment with linezolid should be weighed against the risks associated with its long-term use.
No Reference information available - sign in for access.
No Supplementary Data.
No Article Media
No Metrics

Keywords: M. avium complex; linezolid; multidrug-resistant mycobacterial infections; non-tuberculous mycobacteria; oxazolidinone; tuberculosis

Document Type: Review Article

Affiliations: 1: Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece 2: Alfa Institute of Biomedical Sciences (AIBS), Athens, Greece; Department of Medicine, Henry Dunant Hospital, Athens, Greece; and Department of Medicine, Tufts University School of Medicine, Boston, Massachusetts, USA

Publication date: June 1, 2007

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on lung health world-wide.

    To share scientific research of immediate concern as rapidly as possible, The Union is fast-tracking the publication of certain articles from the IJTLD and publishing them on The Union website, prior to their publication in the Journal. Read fast-track articles.

    Certain IJTLD articles are also selected for translation into French, Spanish, Chinese or Russian. These are available on the Union website.

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more